Mar 07,2022

How Digital Therapeutic Platform 'Limbix' Helps Teens Manage Depression

Ben Lewis, CEO of digital therapeutics platform Limbix, discussed the app helping teens in early stages of depression.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Sober Grid collaborates with Walgreens and Orexo to bring customers Peer Coaching, the Sober Grid community, and Digital Therapeutics

Sober Grid, the world’s largest social media community for those in recovery, continues to expand their reach by joining the Walgreens Find Care® digital health platform. In recent months, Sober Grid has added services such as Orexo’s clinically proven Digital Therapeutics, vorvida® and deprexis®, to assist those suffering from mental health and substance abuse issues. Customers of either of these therapeutics are provided with complimentary Peer Coaching through the Sober Grid app, and Walgreens Find Care users will also have the ability to join Sober Grid’s mobile sober community, which offers live peer coaching, check-ins, and resources.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Twill and Zuellig Pharma Partner to Commercialize Prescription Digital Therapeutics in Asia

Today, Happify Health, the Intelligent Healing Company™, announced it has entered into an out-licensing and distribution deal with Zuellig Pharma for two of its digital therapeutics solutions. Zuellig Pharma, one of the largest healthcare services groups in Asia, will license Ensemble, Happify Health’s transdiagnostic prescription digital therapeutic for people with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) or both, and also license a Prescription Digital Therapeutics for the treatment of Chronic Insomnia. Zuellig Pharma will be deploying these solutions in 13 countries throughout the region.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Woebot Health Secures $9.5 Million Investment From Leaps by Bayer

Woebot Health today announced that Leaps by Bayer, the impact investment arm of Bayer AG, has made a $9.5 million strategic investment in the company to help accelerate further development of its AI-powered behavioral health platform and products. The announcement follows Woebot Health’s $90 million Series B round in 2021 and brings total investment in the company to date to $123.5 million.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 23,2022

DarioHealth Announces Additional New Employer Contracts

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new employer agreements: first, with a U.S. based social platform employer and second, with a global health care company. The contracts are expected to launch in the second quarter of 2022. The social platform company is launching Dario's digital behavioral health solution to improve access to outcomes-based care for its employees; the health care company is deploying Dario's diabetes solution to provide employees with a solution proven to help people improve their health.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 28,2022

A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial

Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

OxfordVR Technology a World First Success in Automating Psychological Therapy Using Virtual Reality (VR)

OxfordVR has successfully automated psychological therapy in VR for patients with mental illness. Users are guided by a virtual coach instead of a real-life therapist, allowing the treatment to reach many more patients. The technology, called gameChangeVR is a 6 week, automated, VR treatment that delivers cognitive behavioral therapy (CBT) inside safe, immersive, virtual scenarios. In the largest ever clinical trial of VR for mental health published today in The Lancet Psychiatry, gameChange was shown to help patients with schizophrenia and mood disorders with psychotic symptoms who suffer anxiety and distress in everyday situations.

PRODUCT

#cbt

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Apr 15,2022

Therapeutic Alliance: Building Relationships With AI Therapy Chatbots

A recent peer-reviewed study in Frontiers of Wysa, an advanced conversational AI for mental health, shows people develop an emotional bond with its chatbot in much the same way people bond with a human therapist. The study of 1,205 people evaluated users of mental health app Wysa who were experiencing measured symptoms of anxiety or depression. The results show that within five days of using Wysa, the therapeutic alliance was comparable or better than scores found in traditional in-person cognitive behavioral therapy (CBT), in-person group therapy and internet-based tools for CBT.

CLINICAL STUDY

#chatbot

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 19,2022

Reulay Inc Announces Results From Study That Highlights the Effects of Reulay’s Digital Video and VR Platform for the Alleviation of Anxiety, Emotional Distress, and Distraction

Reulay, a research-backed mental health platform using AI to match anxiety states to brain-based interventions, today announced data that further underscores the effectiveness of Reulay’s digital video & VR therapeutics. The purpose of this pilot study was to evaluate the safety and use of a nature-based virtual reality (VR) experience among health care providers (HCP) during a pandemic. Twenty-four frontline HCP participated in this crossover pilot where the viewing order of the experiences were randomized. The study results showed that 96% of participants felt relaxed after seeing the imagery, and with respect to anxiety (as measured by the STAI Y1), the VR "Walk in the Woods" had the greatest reduction from pre to post followed by VR "Forest of Focus"

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Apr 19,2022

Freespira Earns Prestigious Quality Reaccreditation From Healthcare Quality Association on Accreditation

Freespira, Inc., maker of the first FDA-cleared digital therapeutic treatment to significantly reduce or eliminate panic attacks, panic disorder and post-traumatic stress disorder (PTSD) symptoms in only 28 days, today announced that it has received a highly coveted and significant quality reaccreditation from The Healthcare Quality Association on Accreditation (HQAA). This accreditation is also a necessary step for continuing access to third-party payment systems and the recently issued CMS code for digital therapeutics products.

PRODUCT

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH